Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 66

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 66
---
 purchased shares of our Class A common stock from the underwriters in the October 2024 Follow-on Offering at the offering price of the shares to the public. The following table sets forth the number of shares of our Class A common stock purchased and the aggregate cash purchase price paid by each of these stockholders.

| Name                                          |     | Shares of Class A 
      Common Stock 
         Purchased |     | Aggregate Cash 
 Purchase Price |
| Fidelity Management & Research Company LLC(1) |     |           119,047 |     |     $4,999,974 |
| Avoro Capital Advisors LLC(2)                 |     |           238,095 |     |     $9,999,990 |
| T. Rowe Price Associates, Inc.(3)             |     |           475,213 |     |    $19,958,946 |

| (1) | Entities affiliated with Fidelity Management & Research Company LLC collectively beneficially owned more than 5% of our outstanding capital stock. |

| (2) | Avoro Capital Advisors LLC owns more than 5% of our outstanding capital stock. |

| (3) | T. Rowe Price Associates, Inc. owns more than 5% of our outstanding capital stock. |

Employment Agreements and Stock Option Grants to Directors and Executive Officers We have entered into employment agreements with certain of our named executive officers, and granted stock options to our named executive officers and certain of our directors, as more fully described in the sections titled “Executive Compensation” and “Director Compensation.”

44

TABLE OF CONTENTS Indemnification We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the Board, as more fully described in the section titled “Limitations on Liability and Indemnification.” With certain exceptions, these agreements provide for indemnification for related expenses including attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. Policies and Procedures for Transactions with Related Persons We maintain a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our Board or our Audit Committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as